Total Payments
$14,248
2019 Payments
$2,550
Companies
2
Transactions
23
Payment Breakdown by Category
Consulting$11,475 (80.5%)
Research$1,732 (12.2%)
Travel$645.20 (4.5%)
Food & Beverage$395.98 (2.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,475 | 2 | 80.5% |
| Unspecified | $1,732 | 9 | 12.2% |
| Travel and Lodging | $645.20 | 4 | 4.5% |
| Food and Beverage | $395.98 | 8 | 2.8% |
Payments by Type
General
$12,516
14 transactions
Research
$1,732
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $12,516 | 14 | $0 (2019) |
| Biogen, Inc. | $1,732 | 9 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $2,550 | 1 | Merck Sharp & Dohme Corporation ($2,550) |
| 2018 | $9,966 | 13 | Merck Sharp & Dohme Corporation ($9,966) |
| 2017 | $1,732 | 9 | Biogen, Inc. ($1,732) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/13/2019 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| 09/06/2018 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $8,925.00 | General |
| 09/06/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 06/15/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 06/15/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $40.01 | General |
| 06/15/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $34.99 | General |
| 06/14/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $235.58 | General |
| 06/14/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $73.00 | General |
| 06/14/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 06/14/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $40.01 | General |
| 06/14/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $34.99 | General |
| 06/13/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $235.58 | General |
| 06/13/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $73.00 | General |
| 06/13/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $24.04 | General |
| 11/11/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $55.65 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
| 11/11/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $33.34 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
| 11/10/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $740.72 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
| 11/10/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $533.90 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
| 11/10/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $62.69 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
| 11/10/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $50.68 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
| 11/10/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $48.02 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
| 11/09/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $137.42 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
| 11/09/2017 | Biogen, Inc. | TYSABRI (Biological) | — | Cash or cash equivalent | $69.30 | Research |
| Study: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy • Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | Biogen, Inc. | $1,732 | 9 |
About Dr. Eugene Butcher, M.D
Dr. Eugene Butcher, M.D is a Anatomic Pathology healthcare provider based in Portola Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/30/2014. The National Provider Identifier (NPI) number assigned to this provider is 1316342546.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eugene Butcher, M.D has received a total of $14,248 in payments from pharmaceutical and medical device companies, with $2,550 received in 2019. These payments were reported across 23 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($11,475).
Ad
Practice Information
- Specialty Anatomic Pathology
- Location Portola Valley, CA
- Active Since 10/30/2014
- Last Updated 10/30/2014
- Taxonomy Code 207ZP0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1316342546
Products in Payments
- TYSABRI (Biological) $1,732
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.